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Fibroblast growth factor 23
mediates the association
between iron deficiency and
mortality in worsening
heart failure
Iron deficiency (ID) is prevalent in heart
failure (HF) and associated with a poor
prognosis.1,2 The pathophysiological mecha-
nisms of ID are not fully understood. While
a strong link between ID and anaemia exists,
ID is associated with increased mortality
in non-anaemic patients as well.3 Addition-
ally, intravenous iron administration is also
beneficial in non-anaemic patients. This
implies other, non-haematopoietic effects
of ID on outcome. ID has been linked to
increased levels of fibroblast growth fac-
tor 23 (FGF23), which is a phosphaturic
osteocyte-derived hormone. FGF23 inhibits
renal phosphate reabsorption and regu-
lates 1,25(OH)2 vitamin D. The association
between iron status and FGF23 originates
from studies in FGF23-related autosomal
dominant hypophosphataemic rickets, which
has an iron-dependent onset.4 Previously,
we have shown that in HF patients, FGF23
is independently associated with congestion,
unsuccessful angiotensin-converting enzyme
inhibitor and angiotensin receptor blocker
up-titration, and poor prognosis.5 Moreover,
FGF23 has been linked to incident HF and
mortality in community-based studies and
development of left ventricular hypertro-
phy and mortality in chronic kidney disease
patients.6,7 Recent preclinical data suggest
an association between FGF23 and cardiac
renin–angiotensin–aldosterone system acti-
vation, thereby leading to cardiac fibrosis and
hypertrophy.8 Finally, correction of ID seems
related to significant reductions in FGF23 lev-
els in HF patients, a finding which further links
iron status and FGF23 together.9 The associa-
tion between iron status, FGF23 and outcome
in HF is currently unclear. This study there-
fore focused on the interplay between iron
and FGF23, and whether FGF23 mediates the
association between iron status and outcome
in HF.
This study is a post-hoc analysis of the ‘sys-
tems BIOlogy Study to TAilored Treatment
in Chronic Heart Failure’ (BIOSTAT-CHF),
which has been described previously.5 In
short, BIOSTAT-CHF prospectively enrolled
2516 patients with worsening signs and/or
symptoms of HF and a left ventricular ejection
fraction≤40% or brain natriuretic peptide lev-
els >400 pg/mL or N-terminal prohormone
of brain natriuretic peptide >2000 pg/mL.
BIOSTAT-CHF was approved by local medical
ethics committees at each participating cen-
tre. We measured the following biomarkers
in 2279 stored samples, drawn at the time of
presentation at the emergency department or
hospital admission: iron, transferrin saturation
(TSAT), ferritin, hepcidin, soluble transferrin
receptor (sTfR) and FGF23 [using a c-terminal
ELISA (Immutopics, Inc., San Clemente, CA,
USA), measuring both intact and c-terminal
FGF23 cumulatively].5 Univariable and multi-
variable linear regression analyses were per-
formed using log-transformed FGF23 levels
as dependent variables and log-transformed
TSAT, sTfR, ferritin and hepcidin as indepen-
dent variables. The multivariable models were
adjusted for predictors that have previously
been associated with FGF23.5 Univariable
and FGF23-adjusted restricted cubic splines
based on Cox proportional hazard regression
were constructed to assess the association
between iron parameters and all-cause mor-
tality. Mediation analyses were performed
according to the methods described by Baron
and Kenny.7
Baseline characteristics of all patients are
depicted in Table 1. Mean (± standard devi-
ation) age of the patients was 69±12 years,
26.1% were female and median (interquartile
range) left ventricular ejection fraction was
30% (25–36%). Patients with higher FGF23
levels were more frequently female, had lower
ferritin, TSAT, and hepcidin levels and higher
levels of inflammatory markers (P for trend
<0.001). FGF23 levels were strongly corre-
lated to TSAT (Spearman’s 𝜌 = −0.42), sTfR
(𝜌 = 0.43), ferritin (𝜌 = −0.31) and hepcidin
(𝜌 = −0.37; all P< 0.0001). Individual levels
of TSAT, sTfR, ferritin and hepcidin were the
strongest predictors of FGF23 levels com-
pared to previously established determinants
of FGF23 levels (all P< 0.001).5 During a
median follow-up of 21 months (interquartile
range 16–27 months), 596 patients (26%)
died. Continuous iron parameter levels were
strongly associated with prognosis in uni-
variable analyses (all P< 0.001) (Figure 1).
When adjusting for FGF23, all iron param-
eters lost their predictive value. There was
a significant interaction between TSAT and
FGF23 on outcome (P= 0.012). Moreover,
we identified a highly significant interaction
between a history of renal disease and FGF23
in the association between iron parameters
and all-cause mortality (P< 0.01). Finally, we
evaluated whether the association between
iron parameters and all-cause mortality was
mediated by FGF23. FGF23 levels significantly
mediated the association between TSAT,
ferritin, sTfR, and hepcidin and all-cause mor-
tality [P for indirect effect (FGF23-mediated)
<0.0001]. The direct effect (non-FGF23-
mediated) was not significant for all iron
parameters in these models (Table 1). As a
sensitivity analysis, we also evaluated whether
inflammation alters the association between
iron status and outcome. Adjustment for
C-reactive protein and interleukin-6 did not
affect the prognostic consequences of iron
parameters.
In this study, we found that in a large, multi-
national cohort of worsening HF patients,
iron parameters are independently related
to FGF23 levels. Second, the prognostic
value of iron parameters is significantly
mediated by FGF23. Taken these findings
together, our data provide insight into
the pathophysiology of ID in HF patients,
in which FGF23 may play a prominent
role.
Low iron has previously been identified as
one of the drivers of FGF23 production in
vivo.4,10 By stabilizing hypoxia-inducible factor
1-𝛼, ID up-regulates the expression of the
proprotein convertase furin, which in turn
increases FGF23 production and cleavage
into intact and c-terminal FGF23.4,11 Obser-
vational studies in chronic kidney disease
and general population cohorts identified
an association between ID and outcome,
which was mediated by FGF23. For example,
an observational study in renal transplant
recipients yielded comparable results to our
study, showing that the association between
ID and outcome is considerably mediated
by FGF23 levels and not by inflammation.7
Furthermore, FGF23 was strongly linked to
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics, stratified by fibroblast growth factor 23 levels in tertiles, and multivariable
























. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics
Age (years) 69±12 66±11 70±12 70±12 <0.001
Women 600 (26.1) 162 (21.1) 201 (26.2) 237 (31.0) <0.001
BMI (kg/m2) 27.9± 5.4 28.0± 4.9 27.7± 5.7 28.0± 5.7 0.381
LVEF (%) 30 (25–36) 30 (25–35) 30 (25–37) 30 (23–37) 0.247
HF aetiology
Ischaemic 1045 (46.3) 345 (45.6) 339 (45.4) 361 (47.9) 0.369
Cardiomyopathy 577 (25.6) 245 (32.4) 176 (23.6) 156 (20.7) <0.001
Hypertension 232 (10.3) 77 (10.2) 89 (11.9) 66 (8.8) 0.13
Valvular disease 169 (7.5) 23 (3.0) 63 (8.5) 83 (11.0) <0.001
Other 130 (5.8) 29 (3.8) 55 (7.4) 46 (6.1) 0.012




55±11 58±12 55±11 52± 9 <0.001
KCCQ score 50± 22 59± 21 49± 21 40± 21 <0.001
Laboratory
Iron (mg/dL) 45 (28–73) 62 (39–84) 45 (28–73) 34 (22–56) <0.001
Transferrin
(mg/dL)
200 (160–250) 200 (170–240) 200 (160–250) 210 (160–260) 0.006
Iron deficiencyb 1413 (61.5) 323 (42.2) 474 (61.9) 616 (80.5) <0.001
Hepcidin
(nmol/L)






















IL-6 (pg/mL) 5.1 (2.8–10.2) 3.0 (1.8–5.6) 5.1 (3.0–8.9) 8.6 (5.0–16.1) <0.001
CRP (mg/L) 13 (6–26) 8 (4–19) 14 (6–26) 18 (9–32) <0.001
Haemoglobin
(g/dL)
13.2± 1.9 13.8±1.6 13.3±1.9 12.6± 1.9 <0.001

















125 (5.4) 31 (4.0) 41 (5.4) 53 (6.9) 0.013
ACEi/ARBs 1662 (72.4) 601 (78.5) 565 (73.8) 496 (64.8) <0.001
ACEi/ARBs (on
target dose)
300 (13.1) 133 (17.4) 99 (12.9) 68 (8.9) <0.001
Loop diuretics 2287 (99.6) 760 (99.2) 763 (99.6) 764 (99.9) 0.053
Aldosterone
antagonists
1235 (53.8) 421 (55.0) 403 (52.6) 411 (53.7) 0.628
Proton pump
inhibitors
806 (35.1) 213 (27.8) 269 (35.1) 324 (42.4) <0.001
P2Y12 inhibitors 356 (15.5) 137 (17.9) 118 (15.4) 101 (13.2) 0.011
Oral
anticoagulants
881 (38.4) 225 (29.4) 333 (43.5) 323 (42.2) <0.001
Values are given as mean ± standard deviation, n (%), or median (interquartile range).
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; FGF23, fibroblast growth factor 23; IL-6,
interleukin-6; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic peptide; sTfR, soluble transferrin receptor.
aMediation analysis was performed for transferrin saturation, sTfR, ferritin and hepcidin. The direct effect is the effect of the respective iron status parameter on all-cause mortality after correcting for
FGF23; the indirect effect is the FGF23-mediated effect of the respective iron status parameter on all-cause mortality. The total effect of iron status on mortality is a composite of the indirect (FGF23-
related) and direct (non-FGF23-related) pathways. CIs are bootstrapped 2000 times. The mediation model is corrected for age, haemoglobin, NT-proBNP, serum urea, and the use of beta-blockers at
baseline.
bIron deficiency was defined as transferrin saturation <20%.








































































































































































































































Figure 1 Association between iron status parameters (transferrin saturation, ferritin and soluble transferrin receptor) and all-cause mortality,
before and after correction for fibroblast growth factor 23 (FGF23). Data were fit by Cox proportional hazard regression models using restricted
cubic splines. CI, confidence interval; HR, hazard ratio.
iron parameters in these patients, similar to
our findings.
Given the strong link between iron status
and FGF23 levels, one may expect changes
in FGF23 levels after iron administration.
Conflicting data have been published on
the effect of intravenous iron administra-
tion on FGF23 levels. In a small cohort of
iron-deficient patients with HF and reduced
ejection fraction, c-terminal FGF23 levels
decreased after ferric carboxymaltose (FCM)
administration during 28 days of follow-
up, with transient hypophosphataemia and
short-term increase in intact FGF23 levels.9
Contrarily, another study comparing FCM
and iron sucrose in haemodialysis patients
found a short-term drop in intact FGF23
and a rise in c-terminal FGF23 in patients
receiving FCM, whereas iron sucrose did not
affect these parameters.12 Currently, no large
studies on the effect of different iron agents
on FGF23 levels in HF have been published.
When intravenous iron therapy substantially
and persistently lowers FGF23 levels, this
might provide an additional explanation for
the mode of action of this treatment modality,
besides its beneficial haematological effects.
























































































































































Our study has several strengths and
limitations. First, we used a large and well-
described cohort of worsening HF patients,
in which we measured FGF23 and multi-
ple iron parameters. We acknowledge the
observational nature of our study, making it
challenging to directly study pathophysiolog-
ical mechanisms. Second, using the FGF23
assay we used for our study, we could not dis-
tinguish c-terminal FGF23 from intact FGF23.
Finally, most patients in BIOSTAT-CHF have
a reduced ejection fraction. Our data should
therefore be cautiously interpreted in HF
patients with a preserved ejection fraction.
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